Manipulation of a patient's genome for therapeutic ends is being attempted through numerous methods, some of which have resulted in disease-modifying interventions. The much anticipated promise of somatic gene therapy is starting to pay off; however, there remain many scientific unknowns, including concerns about safety and durability. A significant ethical concern is that of access to these novel interventions, an issue that is normally framed in terms of the high costs of approved products. I describe how access issues permeate gene therapy long before there is any commercial product and how even upstream decisions—such as choices of indication to pursue, viral vector, and where to site a trial—have significant implications for access to resultant products in both the developmental and commercial stages.

Alison Bateman-House

Annual Review of Genomics and Human Genetics

自 2000 年出版的《基因组学和人类遗传学年度回顾》涵盖了基因组学领域的重大发展，因为它们适用于人类遗传学和人类基因组。我们对基因组技术、基因组结构和功能、基因改造、人类变异和群体遗传学、人类进化以及更重要的是人类遗传疾病的各个方面以及包括个体化医学等领域都特别感兴趣。

Since its inception in 2000, the Annual Review of Genomics and Human Genetics has covered significant advancements in the field of genomics, particularly as they relate to human genetics and the human genome. We are particularly interested in various aspects of genomic technologies, genomic structure and function, genetic modification, human variation and population genetics, human evolution, and, importantly, human genetic diseases, including fields such as personalized medicine.

《Annual Review of Genomics and Human Genetics》自2000年出版以来，涵盖了基因组学领域的重要进展，特别是与人类遗传学和人类基因组相关的研究。我们关注基因组技术、基因组结构与功能、基因改造、人类变异与群体遗传学、人类进化，以及人类遗传疾病等多个方面，尤其是个体化医学等领域。

Category	Quartile
生物学	2
生物学, 遗传学	2

Somatic Gene Therapy: Ethics and Access

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
GENETICS & HEREDITY	1